Chinese Pharmaceutical Market Outlook 2009-2024

Table of Contents

1 Executive Summary

• 1.1 Crucial Aspects of this Report
  • 1.1.1 China' s Economy: Growing Despite Credit Crisis
  • 1.1.2 China' s Healthcare Stimulus
• 1.2 Aims, Scope and Format of this Report
  • 1.2.1 China: The Market to Watch Carefully
  • 1.2.2 Contents Breakdown: Four Types of Forecasts
  • 1.2.3 Chapter Outline
• 1.3 Research Methods

2 Chinese Market Overview

• 2.1 Whole-Market Forecast, 2009-2024 ($bn)
• 2.2 China' s $124bn Healthcare Stimulus for 2009-2020
• 2.3 Sectors Most Likely to Benefit from the Healthcare Stimulus Plan
• 2.4 Visiongain' s Assessment of the Impact of the Healthcare Stimulus Plan on Pharmaceutical Sales
  • 2.4.1 The Impact of Separating Pharmacies from Hospitals
  • 2.4.2 The Need to Support Hospitals
• 2.5 Pricing Policies (Pre-Stimulus Reform)
  • 2.5.1 Price Controls Set by National Reform and Development Commission
  • 2.5.2 Critiques of Price-Control Effectiveness
  • 2.5.3 Subsidised Drugs
  • 2.5.4 Patient-Level Prices: Producers Receive Under 40%
  • 2.5.5 Sales of Prescription Drugs
• 2.6 China: Predicted to Have Largest World Economy by 2040
• 2.7 Brief Overview of China' s Healthcare Situation
• 2.8 China' s Healthcare Costs: Some Crucial Data
• 2.9 China Seeking to Improve Research and Development Profile
  • 2.9.1 Intellectual Property Rights: Length of Patents and Protection Situation
  • 2.9.2 Patent-Granting Authority and Patent Life
  • 2.9.3 Innovation Companies and Departments
• 2.10 Zhangjiang Hi-Tech Science Park: Doubling R&D Output in Three Years
  • 2.10.1 R&D Tax Benefits
  • 2.10.2 Facilitating Strategic Alliances
  • 2.10.3 Timeline for the Zhangjiang Project
  • 2.10.4 CROs in Zhangjiang Hi-Tech Park: Gaining Access to the European Market
• 2.11 Disease Burdens in China: Some Crucial Tables and Figures
  • 2.11.1 Leading Causes of Death in China
  • 2.11.2 Respiratory Diseases
  • 2.11.3 Cancer
  • 2.11.4 Diabetes
  • 2.11.5 Obesity, Cholesterol and Cardiovascular Disease

3 Prescription Pharmaceutical Market Forecasts, 2009-2024

• 3.1 China: Pharma Growth Forecast 2009-2014
• 3.2 China: Pharma Growth Forecast 2014-2024
• 3.3 Pharmaceutical Market Breakdown by Categories
• 3.4 Antibiotics and Anti-Infectives
  • 3.4.1 Types of Antibiotics Sold in China
  • 3.4.2 Antibiotics: Sales Growing but Losing Market Share
  • 3.4.3 Antibiotics Became Prescription-Only in July 2004
  • 3.4.4 Prevalence of Adverse Reactions to Antibiotics
  • 3.4.5 Alleged Over-Prescription Likely to Continue?
• 3.5 Traditional Chinese Medicines (TCMs)
  • 3.5.1 Definition of TCM in this Report
  • 3.5.2 TCMs: Growing Through to 2024, Though Market Share Will Diminish
  • 3.5.3 TCMs in the Home and in Hospitals
  • 3.5.4 TCM and Approaches to Health and National Identity
  • 3.5.5 Perceptions of TCM versus Western Medicine: Speed and Side Effects
  • 3.5.6 Export and Government Promotion of TCMs
• 3.6 Vasotherapeutics / Vasodilators
  • 3.6.1 Retaining Market Share through to 2024
  • 3.6.2 Drugs Included in the Vasotherapeutics Category
  • 3.6.3 Vasotherapeutics: Promoting Vitality
• 3.7 Solutions
  • 3.7.1 Products Included as "Solutions"
  • 3.7.2 Solutions Market Growing More Quickly than the Overall Market Through to 2019, then More Slowly Through to 2024
  • 3.7.3 Key Marketing Companies in China: Shijiazhuang No. 4 and Baxter International
• 3.8 Antiulcerants
  • 3.8.1 One of the Highest Growth-Rate Categories from 2019-2024
  • 3.8.2 Drugs Included in the Antiulcerants Category
  • 3.8.3 Antiulcerants Pipeline
• 3.9 Immunostimulating Agents
  • 3.9.1 Immunostimulating Agents: How Fast Will Market Growth Be in China?
  • 3.9.2 The Pipeline: Promising, but Subject to High Failure Rates
  • 3.9.3 China' s Cancer Rate Rising
• 3.10 Diabetes Treatments
  • 3.10.1 Sales Accelerating Through 2015 and Strong Through to 2024
  • 3.10.2 Insulin and Antidiabetics
  • 3.10.3 Novo Nordisk Building Insulin Factory in China
  • 3.10.4 Novo Nordisk and Insulin: Benefiting from Intra-Country Sales
• 3.11 Vaccines (and Others)
  • 3.11.1 Vaccines: An Important but Relatively Closed Market
  • 3.11.2 China is the Largest Vaccine Consumer in the World
  • 3.11.3 Chinese Vaccine Manufacturing
  • 3.11.4 Chinese Vaccine Research and Development
  • 3.11.5 Sinovac Receives Swine Flu Orders from Beijing
  • 3.11.6 Sinovac Begins Testing H1N1 Vaccine in People
  • 3.11.7 Swine Flu Vaccines and Hualan Biological Engineering Inc.
  • 3.11.8 Swine Flu Vaccine Yields Accumulate Slowly

4 Generics, Branded and Over-the-Counter Drugs in China: Market Breakdown and Forecasts

• 4.1 Prescription Drugs: Branded versus Generics Value Forecasts, 2009-2024
• 4.2 Prescription Drugs: Branded versus Generics Volume Forecasts, 2009-2024
• 4.3 Prescription Drugs: Branded versus Generic Drugs Value as Market Share Percentage, 2009-2024
• 4.4 Summary Figures: Generics and Branded Drugs
• 4.5 OTC Market Compared to Prescription Market
  • 4.5.1 OTC and Prescription Markets: Sales Growth from 2009
  • 4.5.2 OTC Market Growing More Quickly than the Prescription Market Throughout the Forecast Period?
• 4.6 Over-the-Counter Market: How Will This Market Compare with Others in China?
  • 4.6.1 Categories Included in Over-the-Counter Forecast

5 Multinational Corporations Investing in China

• 5.1 GlaxoSmithKline
  • 5.1.1 Conducting Neurodegenerative Research in China Since 2007
  • 5.1.2 Influenza Vaccines Joint Venture with Shenzhen Neptunus
• 5.2 NeoStem: Pre-Disease, Adult Stem Cell Harvesting and Storage
  • 5.2.1 NeoStem and Enhance BioMedical Holdings Ltd (Shanghai)
  • 5.2.2 NeoStem and Suzhou Erye Pharmaceuticals Company, Ltd
• 5.3 Bayer Schering Pharma: Investing in Its Third-Largest Market
  • 5.3.1 Investing $129m in Research and Development Centre in Beijing
  • 5.3.2 In Talks with Tsinghua University
• 5.4 Sanofi-Aventis
  • 5.4.1 Influenza Vaccines Facility in Shenzhen
  • 5.4.2 Helping to Treat Diabetes in China
  • 5.4.3 Partnership with the Chinese Diabetes Society
• 5.5 Novo Nordisk: Producing Insulin in China
  • 5.5.1 Donation of a License to Novo Nordisk' s Small-Molecule Compound Library
• 5.6 Roche: Expanding R&D Facilities and Seeking Partnerships
• 5.7 AstraZeneca: Investing in R&D in China
  • 5.7.1 Oncology R&D
  • 5.7.2 Schizophrenia and New Drug Partnerships
  • 5.7.3 Research Fund for COPD Research
• 5.8 Pfizer: Seeking Acquisitions and Partnerships in China

6 Selected Domestic Companies

• 6.1 Sinovac Biotech Ltd. (Beijing Kexing Bioproducts): Human Vaccine Products
  • 6.1.1 Sinovac Receives Swine Flu Orders from Beijing
  • 6.1.2 Sinovac' s Revenues Depend on a Small Number of Products
  • 6.1.3 Sinovac' s Solvency and its R&D Power
• 6.2 WuXi AppTec: Leading Contract Research and Development
  • 6.2.1 WuXi' s 2008 Performance
  • 6.2.2 Maintaining Customer Satisfaction
  • 6.2.3 WuXi and AstraZeneca: Partnership Extended in 2008
• 6.3 Mindray Medical International: Medical Devices
  • 6.3.1 Product Penetration
  • 6.3.2 Mindray' s Financial Successes: Q1 2009 Growth of Nearly 70% in International Markets
• 6.4 China Nepstar Chain Drugstore Ltd. (Nepstar): Moving Towards Chain-Store Pharmacies
  • 6.4.1 Financial Performance and NYSE Listing
  • 6.4.2 Chain Stores: The Future of Chinese Pharmacies?
• 6.5 Hualan Biological Engineering Inc. (Hualan Biological Engineering Ltd.): The Top Blood Product Company
  • 6.5.1 Hualan Testing Swine Flu Vaccine: Results Expected in September 2009
• 6.6 Tianyin Pharmaceutical Co., Inc.: Modernised Traditional Chinese Medicine
  • 6.6.1 Financial Performance and Expectations
• 6.7 Guilin Sanjin Pharmaceutical Co. Ltd.: China' s First IPO in 2009
• 6.8 Guangzhou Pharmaceuticals Corporation / Guangzhou Pharmaceutical Company, Ltd.
  • 6.8.1 Affiliation with BMP Sunstone Corporation / Sunstone Pharmaceuticals Co. Ltd. / BMP China
  • 6.8.2 Guangzhou and British Company Alliance Boots plc.
• 6.9 China Sky One Medical, Inc.
  • 6.9.1 China Sky One Medical' s Wholly-Owned Subsidiaries
  • 6.9.2 Financial Information: Revenues Grow 100% over Q1 2008
  • 6.9.3 September 2008 Acquisition of Jin Chuang
• 6.10 Harbin Pharmaceutical Group Holding Company, Ltd.
• 6.11 CSPC Pharmaceutical Group Limited (CSPC Pharma)
  • 6.11.1 Financial Summary: 48% Increase in Net Profits for First Four Months of 2009
  • 6.11.2 Moving from APIs to Finished OTC Products
  • 6.11.3 CSPC Pharma Patents and Pipeline
  • 6.11.4 China Pharma Holdings: SFDA Approval for Generic Crestor Clinical Trial
• 6.12 China Medical Technologies: In Vitro Diagnostics Specialists
  • 6.12.1 Financial Summary: Adjusted Income Increased 79% Year-Over-Year 2008-2009
• 6.13 China National Biotec Group (CNBG)
  • 6.13.1 CNBG' s Future Trajectory
  • 6.13.2 CNBG, PATH, and Chengdu Institute of Biological Products: Advancing Cost-Effective Vaccines for the Developing World
• 6.14 China National Pharmaceutical Corporation (Sinopharm): Holding the Nation' s Medicines Reserve
• 6.15 Shenyang Sunshine Pharmaceutical Company Limited (Sunshine)
  • 6.15.1 Financial Summary: First Quarter 2009 Net Revenues Increase 23.7% over First Quarter 2009

7 Chinese Market Conditions: Drivers and Restraints

• 7.1 Strengths and Weaknesses
• 7.2 Opportunities and Threats
• 7.3 Market Highly Fragmented: 3000-6000 Manufacturers and 15,000 Distributors
  • 7.3.1 Nepstar and the Chain Store Pharmacy: Changing the Nature of Distribution?
  • 7.3.2 API Companies: Moving Towards Vertical Integration
• 7.4 Moves Towards Greater Privatisation
• 7.5 Mandatory Pricing Schemes / Price Controls
  • 7.5.1 Applications for Independent Pricing: Affecting Drugs' Perceived and Market Values
  • 7.5.2 The 2006 Anti-Corruption Campaign and Prescribing Practices
• 7.6 Active Pharmaceutical Ingredients (APIs)
  • 7.6.1 Proximal Production
  • 7.6.2 Active Pharmaceutical Ingredients: Oversight and Quality Control
  • 7.6.3 International and Domestic Concerns about API Quality
  • 7.6.4 Multinational Corporations Building Their Own Factories
• 7.7 Counterfeit Drugs: A Continuing Problem
  • 7.7.1 Pfizer' s 2003 Anti-Counterfeiting Scheme in Shanghai
  • 7.7.2 Counterfeits and the Internet
  • 7.7.3 Discovery of Counterfeits in Legitimate Distribution Channels
• 7.8 Generics Spreading Abroad: China is Poised to Provide
  • 7.8.1 Safety Questions: Slowing Generics Exports?
• 7.9 Intellectual Property Rights / Laws: Improving Protection
  • 7.9.1 Lack of Regulatory Transparency: Another R&D Challenge in China?

8 Stem Cells in China: An Interview with Dr Stephen Minger, King' s College London, Co-Founder of the London Regenerative Medicines Network

• 8.1 On Why China is a Central Stem Cell Research Region
• 8.2 On Regulatory Conditions in China
• 8.3 On the Major Clinical Difference Between China and Europe/US Trials
• 8.4 On Laboratory Specialties
• 8.5 On Stem Cells Clinical Trials: Brain Cell Transplants
• 8.6 On Non-Approved Stem Cell Collection and Treatment Businesses
• 8.7 On Cord Blood and Public Stem Cells
• 8.8 On ' Stem Cells' as Business Buzzword
• 8.9 On How Stem Cell Funding is Allocated in China

9 China as a Clinical Trials Destination

• 9.1 International Trends Towards Outsourcing/Offshoring
• 9.2 China' s Share of the Clinical Trials Market
• 9.3 China: Promising but Problematic
  • 9.3.1 China' s Market Share Growing Through to 2024
• 9.4 Necessary Phase III Trials in China
• 9.5 More International Investigation Sites Registering for FDA Approval
• 9.6 How Countries Invite More Trials
• 9.7 How Foreign Clinical Trials Help Host Countries
• 9.8 Continuing Challenges for Emerging Outsourcing Markets Such as China
• 9.9 China Pharma Holdings wins SFDA-Approval for Generic Crestor Clinical Trial
• 9.10 China and Generics Clinical Trials
• 9.11 Sundia: Ranked In Top 100 Fastest-Growing Outsourcing Service Providers
  • 9.11.1 Sundia: Shortening Customs Times

10 Conclusions

• 10.1 Key Findings and Data from this Report
• 10.2 Summary Points
  • 10.2.1 Drivers: Population, Domestic and Foreign Investment and Increasing Affluence
  • 10.2.2 Restraints: Poverty, Intellectual Property and Regulatory Difficulties and Uneven Healthcare Penetration

List of Tables

• Table 2.1 Chinese Whole-Market Forecast, 2009-2019 ($bn)
• Table 2.2 Chinese Whole-Market Forecast, 2019-2024 ($bn)
• Table 2.3 Five Policy Points of China' s 2009-2011 Stimulus
• Table 2.4 Pricing Rules in China (Pre-Stimulus Reforms)
• Table 2.5 Top Causes of Death in China, 2002
• Table 2.6 Respiratory Deaths in China by Category, 2002
• Table 2.7 Cancer Deaths in China by Type, 2002 (%)
• Table 2.8 Diabetes Type 2 Prevalence in China by Age Group, 2002
• Table 3.1 Chinese Total Prescription Market Forecast, 2009-2019 ($bn)
• Table 3.2 Chinese Total Prescription Market Forecast, 2019-2024 ($bn)
• Table 3.3 Chinese Pharmaceutical Market Forecast by Drug Category, 2009-2019 ($m)
• Table 3.4 Chinese Pharmaceutical Market Forecast by Drug Category, 2019-2024 ($m)
• Table 3.5 Antibiotics and Anti-Infectives Forecast, 2009-2019 ($m)
• Table 3.6 Antibiotics and Anti-Infectives Forecast, 2019-2024 ($m)
• Table 3.7 Traditional Chinese Medicines Forecast, 2009-2014 ($m)
• Table 3.8 Traditional Chinese Medicines Forecast, 2019-2024 ($m)
• Table 3.9 Vasotherapeutics Forecast, 2009-2019 ($m)
• Table 3.10 Vasotherapeutics Forecast, 2019-2024 ($m)
• Table 3.11 Top Vasotherapeutics Sold in China, by Name and Active Ingredient, 2009
• Table 3.12 Solutions Forecast, 2009-2019 ($m)
• Table 3.13 Solutions Forecast, 2019-2024 ($m)
• Table 3.14 Types of Solutions and Indications
• Table 3.15 Antiulcerants Forecast, 2009-2019 ($m)
• Table 3.16 Antiulcerants Forecast, 2019-2024 ($m)
• Table 3.17 Top Antiulcerants Sold in China, by Name and Active Ingredient, 2009
• Table 3.18 Immunostimulating Agents Forecast, 2009-2019 ($m)
• Table 3.19 Immunostimulating Agents Forecast, 2019-2024 ($m)
• Table 3.20 Diabetes Treatments Forecast, 2009-2019 ($m)
• Table 3.21 Diabetes Treatments Forecast, 2019-2024 ($m)
• Table 3.22 Other Pharmaceuticals Forecast, 2009-2019 ($m)
• Table 3.23 Other Pharmaceuticals Forecast, 2019-2024 ($m)
• Table 4.1 Branded Drugs and Generics Forecasts, 2009-2019 ($bn)
• Table 4.2 Branded Drugs and Generics Forecasts, 2019-2024 ($bn)
• Table 4.3 Relative CAGRs (%)
• Table 4.4 Over-the-Counter Market Forecast, 2009-2019 ($bn)
• Table 4.5 Over-the-Counter Market Forecast, 2019-2024 ($bn)
• Table 5.1 Bayer Schering Pharma China' s Business Divisions and Top 10 Products, 2009
• Table 6.1 China Sky One Medical Wholly-Owned Subsidiaries
• Table 6.2 Sinopharm' s Wholly-Owned Subsidiaries
• Table 6.3 Sinopharm' s Major Joint Ventures
• Table 7.1 Strengths and Weaknesses of the Chinese Market, 2009
• Table 7.2 Opportunities In and Threats to the Market, 2009-2024
• Table 9.1 Clinical Trials: Total Market and China Forecasts, 2009-2024 ($m)
• Table 9.2 Costs and Benefits of Conducting Clinical Trials in China
• Table 9.3 Some Countries Actively Funding Drug Development Infrastructure
• Table 9.4 Benefits and Challenges to Outsourcing Host Countries

List of Figures

• Figure 2.1 Chinese Whole-Market Forecast, 2009-2024 ($bn)
• Figure 2.2 Top Causes of Death in China, 2002
• Figure 2.3 Respiratory Deaths in China by Category, 2002
• Figure 2.4 Cancer Deaths in China by Type (%), 2002
• Figure 2.5 Diabetes Type 2 Prevalence in China, 2002
• Figure 3.1 Total Market Forecast, 2009-2024 ($bn)
• Figure 3.2 Forecast for Three Drug Categories with 2009 Sales Over $2000m, 2009-2024 ($m)
• Figure 3.3 Forecast for Five Drug Categories with 2009 Sales Under $800m, 2009-2024 ($m)
• Figure 3.4 Antibiotics and Anti-Infectives Forecast, 2009-2024 ($m)
• Figure 3.5 Antibiotics and Anti-infectives Category Breakdown by Value and Percentage Share, 2009 ($m, %)
• Figure 3.6 Traditional Chinese Medicines Forecast, 2009-2024 ($m)
• Figure 3.7 Vasotherapeutics Forecast, 2009-2024 ($m)
• Figure 3.8 Solutions Forecast, 2009-2024 ($m)
• Figure 3.9 Antiulcerants Forecast, 2009-2024 ($m)
• Figure 3.10 Immunostimulating Agents Forecast, 2009-2024 ($m)
• Figure 3.11 Diabetes Treatments Forecast, 2009-2024 ($m)
• Figure 3.12 Other Pharmaceuticals Forecast, 2009-2024 ($m)
• Figure 4.1 Branded Drugs and Generics Values Forecasts, 2009-2024 ($bn)
• Figure 4.2 Branded Drugs and Generics Volume Forecasts, 2009-2024 (%)
• Figure 4.3 Branded Drugs and Generics Value as Percentage Forecasts, 2009-2024 (%)
• Figure 4.4 Comparison of Generics and Branded Drugs' Volume and Value Percentages, 2009-2024 (%)
• Figure 4.5 Comparison of Generics and Branded Drugs' Volume and Value Percentages in 2009, 2014, 2019 and 2024 (%)
• Figure 4.6 OTC, Prescription and Total Market Forecasts, 2009-2024 ($bn)
• Figure 4.7 Over-the-Counter Market Forecast, 2009-2024 ($bn)
• Figure 9.1 China: Clinical Trials Market Forecast, 2009-2024 ($m)
• Figure 9.2 China: Clinical Trials Market Share Forecast, 2009-2024 (%)

• Abbott
• Alliance Boots plc
• American California Pharmaceutical Group
• Apotex
• AppTec Laboratory Services Inc.
• Asahi Chemical
• ASKA Pharmaceutical
• AstraZeneca
• Baxter International
• Bayer Schering Pharma
• Beijing Bio-Ekon Biotechnology Co. Ltd
• Beijing Economic and Technological Development Area
• Beijing GP Medical Technologies, Ltd.
• Beijing Yuande Bio-Medical Engineering Co., Ltd
• Biofarm
• BMJ (British Medical Journal)
• BMP China
• BMP Sunstone Corporation
• Bracco
• Bristol-Myers Squibb
• ChemPartner
• Chengdu Institute of Biological Products
• China Academy of Science
• China Chain Stores and Franchise Association (CCSFA)
• China Council for International Investment Promotion (CCIIP)
• China Medical Technologies
• China National Biotec Group
• China National Biotec Group (CNBG)
• China National Corporation of Medicines Ltd.
• China National Group Corporation of Traditional & Herbal Medicine
• China National Immunization Program
• China National Medical Equipment Industry Corporation
• China National Pharmaceutical Foreign Trade Corporation
• China National Pharmaceutical Group Corporation (Sinopharm)
• China National Pharmaceutical Industry Corporation Ltd.
• China Nepstar Chain Drugstore Ltd. (Nepstar)
• China Ostuka Pharmaceutical Co., Ltd.
• China Pharma Holdings
• China Pharmaceutical Advertising Company Ltd.
• China Pharmaceutical Exhibition Corporation
• China Pharmaceutical Group Co., Ltd (China Pharma).
• China Securities Regulatory Commission
• China Sky One Medical, Inc.
• Chinese Diabetes Society
• CMED Technologies, Ltd.
• CSPC Pharmaceutical Group Limited (CSPC Pharma)
• Eli Lilly
• Enhance BioMedical Holdings Ltd (Shanghai)
• Enhance Holding Corporation
• European Agency for the Evaluation of Medicinal Products (EMEA)
• Food and Drug Administration (US FDA)
• Gedeon Richter
• Genentech
• GlaxoSmithKline
• Goldman Sachs
• Guangzhou Medical University
• Guangzhou Pharmaceutical Company Ltd.
• Guangzhou Pharmaceuticals Corporation
• Guilin Sanjin Pharmaceutical Co.
• Harbin First Bio-Engineering Company Limited
• Harbin Medical University
• Harbin Pharmaceutical Group Co. Ltd
• Harbin Pharmaceutical Group Holding Company, Ltd
• Harbin Tian Di Ren Medical Science and Technology Company
• HB Minkang
• HB.SJZ.Shenwei
• HD Biosciences
• Hebei Pharmaceutical Group
• Heilongjiang Haina Pharmaceutical Inc.
• Heilongjiang Tianlong Pharmaceutical, Inc.
• HN Tongyongsany ANG
• Hualan Biological Engineering Inc.
• Hualan Biological Engineering Ltd.
• Il Yang
• IMS Health
• International Federation of Pharmaceutical Manufacturers Associations (IFPMA)
• Jilin University
• Leti
• Livzon
• LN. JZ Aohong
• Medicilon
• Merck
• Millennium
• Mindray Medical International
• Ministry of Health (China)
• National Center for Drug Screening (NCDS)
• National Food and Drug Administration
• National Medicine Administration
• National Reform and Development Commission (NRDC)
• Nature
• NeoStem
• New England Journal of Medicine
• North East Agricultural University
• Novartis
• NovaSector
• Novo Nordisk
• Nycomed
• Orexo
• PATH
• Peking University
• Peng Lai Jin Chuang Company Pharmaceutical Company
• Pfizer
• Psyma Business Research China
• Qingdao Huazhong Pharmaceutical Co. Ltd.
• R&D-based Pharmaceutical Association Committee (RDPAC)
• Roche
• Rottapharm
• Sanjing Pharmaceutical Co. Ltd
• Sanofi Pasteur
• Sanofi-Aventis
• Schwabe
• Shang Pharm
• Shanghai Administration for Industry and Commerce
• Shanghai Institute of Materia Medica, Chinese Academy of Sciences
• Shanghai Jiao Tong University
• Shanghai Municipal Food and Drug Administration
• Shenyang Sunshine Pharmaceutical Company Limited (Sunshine)
• Shenzhen Neptunus Interlong Bio-Technique Co. Ltd.
• Shijiazhuang No. 4
• Shijiazhuang Pharmaceutical Group
• Sichuan Industrial Institute of Antibiotics
• Sino-American Shanghai Squibb Pharmaceutical Ltd.
• Sinopharm Medicine Holding Co., Ltd.
• Sinopharm United Engineering Company Ltd.
• Sino-Swed Pharmaceutical Corp. Ltd.
• Sinovac Biotech Ltd. (Beijing Kexing Bioproducts)
• Special Program for Research and Training in Tropical Diseases (WHO-affiliated)
• State Food and Drug Administration (SFDA)
• State Industrial Property Office (SIPO)
• State Key Lab of Respiratory Disease
• Sucampo
• Sundia
• Sunstone Pharmaceuticals Co. Ltd.
• Suzhou Erye Pharmaceuticals Company, Ltd
• Suzhou Capsule Co., Ltd.
• Takeda
• The Ministry of Labor and Social Security (MOLSS)
• Tianyin Pharmaceutical Co., Inc.
• Tsinghua University
• Tufts Center for the Study of Drug Development (Tufts CSDD)
• Weisheng
• Working Group on Obesity in China
• World Bank
• World Health Organization
• World Trade Organization
• WuXi AppTec
• WuXi PharmaTech Inc.
• Wyeth
• Xian-Janseen Pharmaceutical Ltd.
• Yuhan
• Zhangjiang Group
• Zhangjiang Hi-Tech Park
• Zhognuo
• Zhongrun
• Zhongrun Neimeng